Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke.
Identifieur interne : 000186 ( Ncbi/Curation ); précédent : 000185; suivant : 000187Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke.
Auteurs : Yuji Ueno [Japon] ; Kazuo Yamashiro ; Yasutaka Tanaka ; Masao Watanabe ; Yoshiaki Shimada ; Takuma Kuroki ; Nobukazu Miyamoto ; Masao Daimon ; Ryota Tanaka ; Katsumi Miyauchi ; Hiroyuki Daida ; Nobutaka Hattori ; Takao UrabeSource :
- Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy [ 1573-7241 ] ; 2014.
Descripteurs français
- KwdFr :
- Accident vasculaire cérébral (anatomopathologie), Accident vasculaire cérébral (traitement médicamenteux), Accident vasculaire cérébral (étiologie), Aorte (anatomopathologie), Embolie (), Encéphalopathie ischémique (anatomopathologie), Encéphalopathie ischémique (traitement médicamenteux), Encéphalopathie ischémique (étiologie), Fluorobenzènes (administration et posologie), Fluorobenzènes (usage thérapeutique), Humains, Hypercholestérolémie (), Hypercholestérolémie (traitement médicamenteux), Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (administration et posologie), Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique), Plan de recherche, Plaque d'athérosclérose (), Plaque d'athérosclérose (traitement médicamenteux), Pyrimidines (administration et posologie), Pyrimidines (usage thérapeutique), Rosuvastatine de calcium, Sulfonamides (administration et posologie), Sulfonamides (usage thérapeutique), Échocardiographie transoesophagienne, Études prospectives.
- MESH :
- administration et posologie : Fluorobenzènes, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase, Pyrimidines, Sulfonamides.
- anatomopathologie : Accident vasculaire cérébral, Aorte, Encéphalopathie ischémique.
- traitement médicamenteux : Accident vasculaire cérébral, Encéphalopathie ischémique, Hypercholestérolémie, Plaque d'athérosclérose.
- usage thérapeutique : Fluorobenzènes, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase, Pyrimidines, Sulfonamides.
- étiologie : Accident vasculaire cérébral, Encéphalopathie ischémique.
- Embolie, Humains, Hypercholestérolémie, Plan de recherche, Plaque d'athérosclérose, Rosuvastatine de calcium, Échocardiographie transoesophagienne, Études prospectives.
English descriptors
- KwdEn :
- Aorta (pathology), Brain Ischemia (drug therapy), Brain Ischemia (etiology), Brain Ischemia (pathology), Echocardiography, Transesophageal, Embolism (complications), Fluorobenzenes (administration & dosage), Fluorobenzenes (therapeutic use), Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage), Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use), Hypercholesterolemia (complications), Hypercholesterolemia (drug therapy), Plaque, Atherosclerotic (complications), Plaque, Atherosclerotic (drug therapy), Prospective Studies, Pyrimidines (administration & dosage), Pyrimidines (therapeutic use), Research Design, Rosuvastatin Calcium, Stroke (drug therapy), Stroke (etiology), Stroke (pathology), Sulfonamides (administration & dosage), Sulfonamides (therapeutic use).
- MESH :
- chemical , administration & dosage : Fluorobenzenes, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Pyrimidines, Sulfonamides.
- complications : Embolism, Hypercholesterolemia, Plaque, Atherosclerotic.
- drug therapy : Brain Ischemia, Hypercholesterolemia, Plaque, Atherosclerotic, Stroke.
- etiology : Brain Ischemia, Stroke.
- pathology : Aorta, Brain Ischemia, Stroke.
- chemical , therapeutic use : Fluorobenzenes, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Pyrimidines, Sulfonamides.
- Echocardiography, Transesophageal, Humans, Prospective Studies, Research Design, Rosuvastatin Calcium.
Abstract
Large atheromatous aortic plaques (AAPs) are associated with stroke recurrence. Rosuvastatin is a potent lipid-lowering agent and suppresses carotid and coronary artery atherosclerosis. It is unclear whether rosuvastatin has anti-atherogenic effects against AAPs in stroke patients. We designed a clinical trial in stroke patients to analyze changes in AAPs after rosuvastatin treatment using repeated transesophageal echocardiography (TEE).
DOI: 10.1007/s10557-013-6493-6
PubMed: 24072337
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000013
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000013
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000013
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000186
Links to Exploration step
pubmed:24072337Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke.</title><author><name sortKey="Ueno, Yuji" sort="Ueno, Yuji" uniqKey="Ueno Y" first="Yuji" last="Ueno">Yuji Ueno</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba, 279-0021, Japan, yuji-u@juntendo.ac.jp.</nlm:affiliation><country wicri:rule="url">Japon</country><wicri:regionArea>Department of Neurology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba, 279-0021, Japan</wicri:regionArea><wicri:noRegion>Japan</wicri:noRegion></affiliation></author><author><name sortKey="Yamashiro, Kazuo" sort="Yamashiro, Kazuo" uniqKey="Yamashiro K" first="Kazuo" last="Yamashiro">Kazuo Yamashiro</name></author><author><name sortKey="Tanaka, Yasutaka" sort="Tanaka, Yasutaka" uniqKey="Tanaka Y" first="Yasutaka" last="Tanaka">Yasutaka Tanaka</name></author><author><name sortKey="Watanabe, Masao" sort="Watanabe, Masao" uniqKey="Watanabe M" first="Masao" last="Watanabe">Masao Watanabe</name></author><author><name sortKey="Shimada, Yoshiaki" sort="Shimada, Yoshiaki" uniqKey="Shimada Y" first="Yoshiaki" last="Shimada">Yoshiaki Shimada</name></author><author><name sortKey="Kuroki, Takuma" sort="Kuroki, Takuma" uniqKey="Kuroki T" first="Takuma" last="Kuroki">Takuma Kuroki</name></author><author><name sortKey="Miyamoto, Nobukazu" sort="Miyamoto, Nobukazu" uniqKey="Miyamoto N" first="Nobukazu" last="Miyamoto">Nobukazu Miyamoto</name></author><author><name sortKey="Daimon, Masao" sort="Daimon, Masao" uniqKey="Daimon M" first="Masao" last="Daimon">Masao Daimon</name></author><author><name sortKey="Tanaka, Ryota" sort="Tanaka, Ryota" uniqKey="Tanaka R" first="Ryota" last="Tanaka">Ryota Tanaka</name></author><author><name sortKey="Miyauchi, Katsumi" sort="Miyauchi, Katsumi" uniqKey="Miyauchi K" first="Katsumi" last="Miyauchi">Katsumi Miyauchi</name></author><author><name sortKey="Daida, Hiroyuki" sort="Daida, Hiroyuki" uniqKey="Daida H" first="Hiroyuki" last="Daida">Hiroyuki Daida</name></author><author><name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name></author><author><name sortKey="Urabe, Takao" sort="Urabe, Takao" uniqKey="Urabe T" first="Takao" last="Urabe">Takao Urabe</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="doi">10.1007/s10557-013-6493-6</idno><idno type="RBID">pubmed:24072337</idno><idno type="pmid">24072337</idno><idno type="wicri:Area/PubMed/Corpus">000013</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000013</idno><idno type="wicri:Area/PubMed/Curation">000013</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000013</idno><idno type="wicri:Area/PubMed/Checkpoint">000013</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000013</idno><idno type="wicri:Area/Ncbi/Merge">000186</idno><idno type="wicri:Area/Ncbi/Curation">000186</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke.</title><author><name sortKey="Ueno, Yuji" sort="Ueno, Yuji" uniqKey="Ueno Y" first="Yuji" last="Ueno">Yuji Ueno</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba, 279-0021, Japan, yuji-u@juntendo.ac.jp.</nlm:affiliation><country wicri:rule="url">Japon</country><wicri:regionArea>Department of Neurology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba, 279-0021, Japan</wicri:regionArea><wicri:noRegion>Japan</wicri:noRegion></affiliation></author><author><name sortKey="Yamashiro, Kazuo" sort="Yamashiro, Kazuo" uniqKey="Yamashiro K" first="Kazuo" last="Yamashiro">Kazuo Yamashiro</name></author><author><name sortKey="Tanaka, Yasutaka" sort="Tanaka, Yasutaka" uniqKey="Tanaka Y" first="Yasutaka" last="Tanaka">Yasutaka Tanaka</name></author><author><name sortKey="Watanabe, Masao" sort="Watanabe, Masao" uniqKey="Watanabe M" first="Masao" last="Watanabe">Masao Watanabe</name></author><author><name sortKey="Shimada, Yoshiaki" sort="Shimada, Yoshiaki" uniqKey="Shimada Y" first="Yoshiaki" last="Shimada">Yoshiaki Shimada</name></author><author><name sortKey="Kuroki, Takuma" sort="Kuroki, Takuma" uniqKey="Kuroki T" first="Takuma" last="Kuroki">Takuma Kuroki</name></author><author><name sortKey="Miyamoto, Nobukazu" sort="Miyamoto, Nobukazu" uniqKey="Miyamoto N" first="Nobukazu" last="Miyamoto">Nobukazu Miyamoto</name></author><author><name sortKey="Daimon, Masao" sort="Daimon, Masao" uniqKey="Daimon M" first="Masao" last="Daimon">Masao Daimon</name></author><author><name sortKey="Tanaka, Ryota" sort="Tanaka, Ryota" uniqKey="Tanaka R" first="Ryota" last="Tanaka">Ryota Tanaka</name></author><author><name sortKey="Miyauchi, Katsumi" sort="Miyauchi, Katsumi" uniqKey="Miyauchi K" first="Katsumi" last="Miyauchi">Katsumi Miyauchi</name></author><author><name sortKey="Daida, Hiroyuki" sort="Daida, Hiroyuki" uniqKey="Daida H" first="Hiroyuki" last="Daida">Hiroyuki Daida</name></author><author><name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name></author><author><name sortKey="Urabe, Takao" sort="Urabe, Takao" uniqKey="Urabe T" first="Takao" last="Urabe">Takao Urabe</name></author></analytic><series><title level="j">Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy</title><idno type="eISSN">1573-7241</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aorta (pathology)</term><term>Brain Ischemia (drug therapy)</term><term>Brain Ischemia (etiology)</term><term>Brain Ischemia (pathology)</term><term>Echocardiography, Transesophageal</term><term>Embolism (complications)</term><term>Fluorobenzenes (administration & dosage)</term><term>Fluorobenzenes (therapeutic use)</term><term>Humans</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage)</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term><term>Hypercholesterolemia (complications)</term><term>Hypercholesterolemia (drug therapy)</term><term>Plaque, Atherosclerotic (complications)</term><term>Plaque, Atherosclerotic (drug therapy)</term><term>Prospective Studies</term><term>Pyrimidines (administration & dosage)</term><term>Pyrimidines (therapeutic use)</term><term>Research Design</term><term>Rosuvastatin Calcium</term><term>Stroke (drug therapy)</term><term>Stroke (etiology)</term><term>Stroke (pathology)</term><term>Sulfonamides (administration & dosage)</term><term>Sulfonamides (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Accident vasculaire cérébral (anatomopathologie)</term><term>Accident vasculaire cérébral (traitement médicamenteux)</term><term>Accident vasculaire cérébral (étiologie)</term><term>Aorte (anatomopathologie)</term><term>Embolie ()</term><term>Encéphalopathie ischémique (anatomopathologie)</term><term>Encéphalopathie ischémique (traitement médicamenteux)</term><term>Encéphalopathie ischémique (étiologie)</term><term>Fluorobenzènes (administration et posologie)</term><term>Fluorobenzènes (usage thérapeutique)</term><term>Humains</term><term>Hypercholestérolémie ()</term><term>Hypercholestérolémie (traitement médicamenteux)</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (administration et posologie)</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique)</term><term>Plan de recherche</term><term>Plaque d'athérosclérose ()</term><term>Plaque d'athérosclérose (traitement médicamenteux)</term><term>Pyrimidines (administration et posologie)</term><term>Pyrimidines (usage thérapeutique)</term><term>Rosuvastatine de calcium</term><term>Sulfonamides (administration et posologie)</term><term>Sulfonamides (usage thérapeutique)</term><term>Échocardiographie transoesophagienne</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Fluorobenzenes</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term><term>Pyrimidines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Fluorobenzènes</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term><term>Pyrimidines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Accident vasculaire cérébral</term><term>Aorte</term><term>Encéphalopathie ischémique</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Embolism</term><term>Hypercholesterolemia</term><term>Plaque, Atherosclerotic</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Brain Ischemia</term><term>Hypercholesterolemia</term><term>Plaque, Atherosclerotic</term><term>Stroke</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Brain Ischemia</term><term>Stroke</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Aorta</term><term>Brain Ischemia</term><term>Stroke</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Fluorobenzenes</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term><term>Pyrimidines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Accident vasculaire cérébral</term><term>Encéphalopathie ischémique</term><term>Hypercholestérolémie</term><term>Plaque d'athérosclérose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Fluorobenzènes</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term><term>Pyrimidines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Accident vasculaire cérébral</term><term>Encéphalopathie ischémique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Echocardiography, Transesophageal</term><term>Humans</term><term>Prospective Studies</term><term>Research Design</term><term>Rosuvastatin Calcium</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Embolie</term><term>Humains</term><term>Hypercholestérolémie</term><term>Plan de recherche</term><term>Plaque d'athérosclérose</term><term>Rosuvastatine de calcium</term><term>Échocardiographie transoesophagienne</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Large atheromatous aortic plaques (AAPs) are associated with stroke recurrence. Rosuvastatin is a potent lipid-lowering agent and suppresses carotid and coronary artery atherosclerosis. It is unclear whether rosuvastatin has anti-atherogenic effects against AAPs in stroke patients. We designed a clinical trial in stroke patients to analyze changes in AAPs after rosuvastatin treatment using repeated transesophageal echocardiography (TEE).</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/EpistemeV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000186 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000186 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Ticri/CIDE
|area= EpistemeV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:24072337
|texte= Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:24072337" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a EpistemeV1
| This area was generated with Dilib version V0.6.31. |  |